ArriVent wows investors with promising China-developed lung cancer treatment
The drug startup’s shares rose 11% on their first trading day, after it raised $150 million in an upsized IPO underwritten by three major investment banks Key Takeaways: ArriVent raised…
Recent Articles
RELATED ARTICLES
-
CHINA BULLETIN: Local Governments Crushed by Debt
- CHINA BULLETIN: Services, Trade Send Positive Signals
-
Everest Medicines eyes mRNA tumor vaccines as drug valuations rebound
1952.HK
-
Akeso marks profit milestone with swift rights issue
9926.HK
- CHINA BULLETIN: U.S. Ratchets Up Strategic Tariffs
-
Facing revenue crisis, Ascletis Pharma tries to bulk up with obesity drugs
1672.HK
- CHINA BULLETIN: Manufacturing Déjà Vu
